S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
Brief description of study
If you have been diagnosed with triple negative breast cancer (TNBC) you may qualify to participate in a clinical trial investigating the investigational drug MK-3475. The main purpose of this study is to see if immunotherapy with MK-3475 (pembrolizumab) can lower the risk of recurrence in patients with triple negative breast cancer who have residual cancer identified in the surgical specimen after standard chemotherapy.
Clinical Study Identifier: s16-02231
ClinicalTrials.gov Identifier: NCT02954874
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
